Assessment of multiple dose administration ofglucagon receptor blocker REMD477 in type 1 diabetes
Ended Project Grant Awarded Last action
- Award ID
- R44DK108305
- Recipient
-
Remd Biotherapeutics Inc. UEI DXA8DRFBBBM5
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,968,554
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Funding
-
- $3,974,747.00 Federal
- $993,807.00 Non-federal
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $993,807 | $0 | |
| Amendment | $993,807 | $993,807 | |
| Amendment | $993,807 | $0 | |
| Original award | $993,326 | $0 |
Quick answers
Who received award R44DK108305?
R44DK108305 was awarded to Remd Biotherapeutics Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 1, 2016.
How much is award R44DK108305 worth?
$4,968,554 has been obligated on R44DK108305: $3,974,747 in federal funding and $993,807 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award